FDA approves first postmenopausal libido treatment, Addyi

The FDA has expanded approval of Sprout Pharmaceuticals’ Addyi (flibanserin) to include postmenopausal women ages 65 and younger with hypoactive sexual desire disorder (HSDD), making it the first and only FDA‑approved treatment for low libido in that population and extending its 2015 premenopausal indication; HSDD affects an estimated 40–55% of postmenopausal women, implying a materially larger addressable market. Addyi is dosed as a 100 mg tablet at bedtime and carries notable safety and usage constraints—including avoidance of more than three alcoholic drinks until the next day because of severe hypotension and syncope risk—and common adverse effects such as dizziness, somnolence, nausea and fatigue. While testosterone is used off‑label and is not FDA‑approved, the label expansion could boost Sprout’s commercial prospects, although uptake may be tempered by safety warnings, contraindications and the fact that the original pivotal trials were conducted in premenopausal women.

Analysis

The FDA has expanded approval of Sprout Pharmaceuticals’ Addyi (flibanserin) to include postmenopausal women ages 65 and younger with hypoactive sexual desire disorder (HSDD), extending its 2015 premenopausal indication and creating the first FDA-approved option for low libido in that population. HSDD is estimated to affect 40%–55% of postmenopausal women, suggesting a materially larger addressable market versus the premenopausal-only label.

Addyi is dosed as a 100 mg tablet taken at bedtime and carries explicit safety constraints—patients should avoid more than three alcoholic drinks until the next day because of increased risk of severe hypotension and syncope—and common adverse reactions include dizziness, somnolence, nausea, fatigue, insomnia and dry mouth. The original pivotal trials supporting approval were conducted in premenopausal women, which leaves questions about the direct clinical evidence base in postmenopausal patients and may influence prescriber adoption and payer coverage.

Commercial upside exists from first-mover status in an underserved market, but uptake is likely to be tempered by safety warnings, contraindications, and off-label testosterone use that remains common despite lacking FDA approval. Key near-term variables for investors are initial prescription trends, formulary and insurance coverage decisions, and post-marketing safety signals that will determine real-world adoption and revenue trajectory.

Key Decisions for Investors

• Monitor prescription starts, sales releases and major payer formulary decisions over the next 2–4 quarters before increasing exposure to Sprout Pharmaceuticals, as these metrics will confirm commercial uptake
• Limit position size or hedge exposure until early real-world safety data and adverse-event reports clarify the hypotension/syncope risk profile, because the alcohol-related restriction and side-effect frequency could cap market share
• Track clinical guidance from professional societies and any follow-on studies in postmenopausal cohorts; if insurers broadly reimburse and guidelines endorse use, consider scaling exposure, otherwise maintain a cautious stance